Can Oral Therapy Replace Insulin In Diabetes for Those with Cystic Fibrosis?
Pulmonary effects in both patient groups
While it is a breakthrough to find that the two methods of treatment are comparable, that does not mean that either of them are without side effects. Most often, pulmonary events affect almost half of patients, in either treatment. 40% of patients were found to be affected in the repaglinide group and 45% in that of insulin. Therefore, the repaglinide may even be seen to offer an advantage.
